Strong Trigger
now
Amplifies development rate of CRISPR-edited CAR-T therapies for B-cell non-Hodgkin lymphoma following a strategic $25M equity investment from Pfizer.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |